Breaking News

As per Market Industry Reports (MIR) research findings, standardized, scalable, integrated hemophilia treatment solutions set to open new avenues for stakeholders.

Global hemophilia treatment market is estimated to be over US$ 11.2 Bn in 2018. It is anticipated to grow at 5.7% CAGR from 2019 to 2026.

Growth in hemophilia treatment market can be attributed to several factors such as increasing prevalence of hemophilia worldwide, extensive research and development for improving diagnosis and treatment of hemophilia and large pool of pipeline products for efficient treatment of hemophilia. For instance, Spark Therapeutics entered into collaboration with Pfizer for advancing and developing products to treat hemophilia using gene therapy such as SPK-FIX.

The global Hemophilia Treatment market is largely governed by prominent players such as Baxter, Grifols S.A., CSL Ltd., Novo Nordisk A/S, Kedrion S.p.A, Pfizer Inc., Bayer AG, Sanofi, Takeda, Octapharma among others.

Get FREE Sample Copy with TOC to understand the structure of the complete report @ https://www.marketindustryreports.com/pdf/109

Reimbursement offered by government agencies and pharmaceutical companies in specific regions have contributed in extensive growth of the global hemophilia treatment market. For instance in England, all services and treatments for hemophilia are paid directly by NHS England through specialized services.

MARKET ECOSYSTEM/CLASSIFICATION

By Type

  • Hemophilia A
  • Hemophilia B
  • Others [Von Willebrand disease (VWD), Other Factor Deficiencies and Others]

By Treatment

  • Replacement Therapy
  • ITI (Immune Tolerance Induction) Therapy
  • Gene Therapy

By Therapy

  • Demand
  • Prophylaxis

Buy Full Report @ https://www.marketindustryreports.com/checkout/109

From a regional perspective, Europe is expected to witness highest CAGR in the coming years due to increasing prevalence of hemophilia A, launch of new products and rising investment for the production of novel and more efficient treatment for hemophilia. For instance, Ireland is the first European country that substituted their hemophilia A and B treatment from clotting factors which are short lived to new generation extended half-life (EHL) therapies. North America has the largest share of the hemophilia treatment market. The large share of this market segment can be attributed to the increasing healthcare research facilities and growing recombinant coagulation factor concentrate products in the U.S. as well as Canada.

REASONS TO BUY THE REPORT:

  • Deep-rooted quantitative and qualitative insights at segment and sub-segment level
  • Global insights with country levels information
  • Comprehensive insights on market dynamics, and business environment
  • Exhaustive coverage on competitive landscape
  • Insights on ‘Key Strategies’ followed by leading players of the market
  • Access to ‘Latest Strategic Developments’ registered by leading players of the market

For deep rooted insights on this topic, please visit @ https://www.marketindustryreports.com/hemophilia-treatment-market/109

CUSTOMIZATION OPTIONS:

  • Key Distributors List
  • Free addition of ‘Company Profiles’
  • Clientele Base Assessment

ABOUT US:

Market Industry Reports is a global leader in market measurement and advisory services, Market Industry Reports is at the forefront of innovation to address the worldwide industry trends and opportunities. We identified the caliber of market dynamics and hence we excel in the areas of innovation and optimization, integrity, curiosity, customer and brand experience, and strategic business intelligence through our research.

CONTACT US:

502, Sai Radhe, Kennedy Road,
Behind Hotel Sheraton Grand,
Near Pune Station, Pune 411 001,Maharashtra, India
[email protected]
+1 347 767 5477 ( US )
+44 131 463 4161 ( UK )
+ 91 8956 767 535 ( IN )

Press Release Distributed by The Express Wire

To view the original version on The Express Wire visit Hemophilia Treatment Market Trends in-Depth Analysis by Industry Top Players 2019-2026: Bayer AG, Sanofi, Takeda, Octapharma, Baxter, Grifols S.A.